Quick answer
What is Lixisenatide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Lixisenatide is a peptide, grouped on this site under Incretin receptor agonists, and the 12 research records kept here are 2 from studies in rats or mice, 9 from trials in people and 1 that does not state what kind of study it is.
The literature search returned 698 records. This site keeps 12 of them, which is 1.7 per cent of what came back.
What it is
This site puts it in the Incretin receptor agonists group.
A once-daily GLP-1 receptor agonist, per the retrieved records, with reported effects on postprandial glycaemic control and gastric emptying.[1, 2]
Stated in the titles of the cited 2012 Diabetes, Obesity and Metabolism and 2015 Diabetes Care papers.
What kind of records
Several of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 9 of 12 indexed records are interventional human trials by their own assigned publication type.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 686 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes, obesity & metabolism (2012). pmid:22564709
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial. Diabetes care (2015). pmid:25887358